MedVellum
Clinical Atlas OS
CICM Fellowship atlas
Intensive Care Medicine
High Evidence
AI-generated

Pulmonary Hypertension in ICU

Pulmonary hypertension (PH) in ICU represents a critical intersection of elevated pulmonary vascular resistance and righ... CICM Second Part Written, CICM Secon

AI
Content
Generated education
25 Jan 2026
Updated
1 min
Read time
Answer card

What matters first

Clinical frame

Pulmonary hypertension (PH) in ICU represents a critical intersection of elevated pulmonary vascular resistance and righ... CICM Second Part Written, CICM Secon

Do not miss

Check the red flags, emergency triggers, and escalation points before using the deep-dive material.

Updated

25 Jan 2026

AI disclosure

Generated educational material; verify before clinical use.

Evidence

Evidence import pending

Content status
AI-generated educational content
Reviewer claim
No individual clinician credential claimed

Clinical board

A visual summary of the highest-yield teaching signals on this page.

Exam focus

Current exam surfaces linked to this topic.

  • CICM Second Part Written
  • CICM Second Part Hot Case
  • CICM Second Part Viva

Content status and exam context

This page is AI-generated educational content. It may contain errors or omissions and is not a substitute for current guidelines, local protocols, senior clinical judgement, or professional medical advice.

MedVellum does not claim an individual clinician reviewer, board certification, or professional credential for this page unless a future version names a real, verifiable reviewer.

CICM Second Part Written
CICM Second Part Hot Case
CICM Second Part Viva
Topic guide

Clinical explanation and evidence

Pulmonary Hypertension in ICU

Pulmonary hypertension (PH) in ICU represents a critical intersection of elevated pulmonary vascular resistance and right ventricular (RV) failure. The 2022 ESC/ERS guidelines define PH as mean pulmonary artery pressure (mPAP) ≥20 mmHg at rest (updated from >25 mmHg). ICU management focuses on reducing RV afterload, maintaining RV perfusion pressure (systemic MAP > pulmonary pressures), avoiding hypoxia and hypercarbia, and optimizing preload without volume overload. Inhaled pulmonary vasodilators (nitric oxide, iloprost) are first-line, with systemic therapies (sildenafil, epoprostenol) for stabilization. VA-ECMO is the bridge to recovery or transplant for refractory cases.

Key Points

  1. 2022 Definition: PH is defined as mPAP ≥20 mmHg at rest (changed from >25 mmHg in 2022 ESC/ERS guidelines). Pre-capillary PH requires PVR >2 Wood units.
  2. WHO Classification: Group 1 (PAH), Group 2 (left heart disease - most common), Group 3 (lung disease/hypoxia), Group 4 (CTEPH), Group 5 (multifactorial/unclear mechanisms).

Red Flags

Cardiac Arrest in PH: CPR outcomes dismal (<10% survival). Prevention is paramount. Avoid arrest triggers: hypoxia, arrhythmia, intubation without optimization.